Rescue from cloned cDNAs and in vivo characterization of recombinant pathogenic romero and live-attenuated candid #1 strains of Junin virus, the causative agent of argentine hemorrhagic fever disease

Journal of Virology

Volumn 85, Issue 4, 2011, Pages 1473-1483

  Emonet, Sebastien F ^a   Seregin, Alexey V ^b   Yun, Nadezhda E ^b   Poussard, Allison L ^b   Walker, Aida G ^b   De La Torre, Juan C ^a   Paessler, Slobodan ^b  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; VIRUS RNA; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARGENTINE HEMORRHAGIC FEVER; ARTICLE; CANDID STRAIN; CELL CULTURE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE IDENTIFICATION; GENE SEQUENCE; GENOME; GUINEA PIG; JUNIN VIRUS; LETHALITY; MOLECULAR CLONING; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; RNA REPLICATION; ROMERO VIRUS; VIRAL GENETICS; VIRUS ATTENUATION; VIRUS GENE; VIRUS GENOME; VIRUS PATHOGENESIS; VIRUS REPLICATION; VIRUS STRAIN;

ANIMALS; ANTIBODIES, VIRAL; ARENAVIRIDAE INFECTIONS; BASE SEQUENCE; CELL LINE; CERCOPITHECUS AETHIOPS; CLONING, MOLECULAR; CRICETINAE; DNA, COMPLEMENTARY; FEMALE; GENOTYPE; GUINEA PIGS; HEMORRHAGIC FEVER, AMERICAN; HUMANS; IMMUNIZATION; JUNIN VIRUS; MOLECULAR SEQUENCE DATA; PHENOTYPE; RECOMBINATION, GENETIC; VACCINES, ATTENUATED; VERO CELLS; VIRAL VACCINES; VIRUS REPLICATION;

ARENAVIRUS; CANDIDA; CAVIA; JUNIN VIRUS;

EID: 78951490910     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02102-10     Document Type: Article

References (32)

1. Albariño, C. G., et al. 2009. Efficient reverse genetics generation of infectious Junin viruses differing in glycoprotein processing. J. Virol. 83:5606-5614.
2. Albariño, C. G., et al. 2011. Reverse genetics generation of chimeric infectious Junin/Lassa virus is dependent on interaction of homologous glycoprotein stable signal peptide and G2 cytoplasmic domains. J. Virol. 85:112-122.
3. Andrei, G., and E. De Clercq. 1993. Molecular approaches for the treatment of hemorrhagic fever virus infections. Antiviral Res. 22:45-75. (Pubitemid 23256719)
4. Buchmeier, M. J., M. D. Bowen, and C. J. Peters. 2001. Arenaviridae: the virus and their replication, p. 1635-1668. In D. M. Knipe and P. M. Howley (ed.), Fields virology, fourth ed., vol. 2. Lippincott Williams & Wilkins, Philadelphia, PA.
5. Buchmeier, M. J., C. J. Peters, and J. C. de la Torre. 2007. Arenaviridae: the viruses and their replication, p. 1792-1827. In D. M. Knipe and P. M. Howley (ed.), Fields virology, fifth ed., vol. 2. Lippincott Williams & Wilkins, Philadelphia, PA.
6. Chen, M., et al. 2008. Genomic and biological characterization of aggressive and docile strains of lymphocytic choriomeningitis virus rescued from a plasmid-based reverse-genetics system. J. Gen. Virol. 89:1421-1433.
7. Damonte, E. B., and C. E. Coto. 2002. Treatment of arenavirus infections: from basic studies to the challenge of antiviral therapy. Adv. Virus Res. 58:125-155.
8. Emonet, S. F., L. Garidou, D. B. McGavern, and J. C. de la Torre. 2009. Generation of recombinant lymphocytic choriomeningitis viruses with trisegmented genomes stably expressing two additional genes of interest. Proc. Natl. Acad. Sci. U. S. A. 106:3473-3478.
9. Enria, D. A., and J. G. Barrera Oro. 2002. Junin virus vaccines. Curr. Top. Microbiol. Immunol. 263:239-261.
10. Enria, D. A., A. M. Briggiler, and Z. Sanchez. 2008. Treatment of Argentine hemorrhagic fever. Antiviral Res. 78:132-139.
11. Goñi, S. E., et al. 2006. Genomic features of attenuated Junin virus vaccine strain candidate. Virus Genes 32:37-41.
12. Goñi, S. E., et al. 2010. Molecular analysis of the virulence attenuation process in Junin virus vaccine genealogy. Virus Genes 40:320-328.
13. Harrison, L. H., et al. 1999. Clinical case definitions for Argentine hemorrhagic fever. Clin. Infect. Dis. 28:1091-1094.
14. Johnson, K. M., et al. 1987. Clinical virology of Lassa fever in hospitalized patients. J. Infect. Dis. 155:456-464.
15. Lan, S., et al. 2009. Development of infectious clones for virulent and avirulent Pichinde viruses: a model virus to study arenavirus-induced hemorrhagic fevers. J. Virol. 83:6357-6362.
16. Lee, J. S., A. G. Hadjipanayis, and M. D. Parker. 2005. Viral vectors for use in the development of biodefense vaccines. Adv. Drug Deliv. Rev. 57:1293-1314.
17. Maiztegui, J. I., et al. 1998. Protective efficacy of a live attenuated vaccine against Argentine hemorrhagic fever. J. Infect. Dis. 177:277-283.
18. Matloubian, M., S. R. Kolhekar, T. Somasundaram, and R. Ahmed. 1993. Molecular determinants of macrophage tropism and viral persistence: importance of single amino acid changes in the polymerase and glycoprotein of lymphocytic choriomeningitis virus. J. Virol. 67:7340-7349.
19. McCormick, J. B., and S. P. Fisher-Hoch. 2002. Lassa fever, p. 75-110. In M. B. Oldstone (ed.), Arenaviruses I, vol. 262. Springer-Verlag, Berlin, Germany.
20. McKee, K. T., Jr., J. G. Oro, A. I. Kuehne, J. A. Spisso, and B. G. Mahlandt. 1992. Candid No. 1 Argentine hemorrhagic fever vaccine protects against lethal Junin virus challenge in rhesus macaques. Intervirology 34:154-163.
21. Meyer, B. J., and P. J. Southern. 1994. Sequence heterogeneity in the termini of lymphocytic choriomeningitis virus genomic and antigenomic RNAs. J. Virol. 68:7659-7664.
22. Moskophidis, D., F. Lechner, H. Pircher, and R. M. Zinkernagel. 1993. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature 362:758-761.
23. Parodi, A. S., et al. 1958. Concerning the epidemic outbreak in Junin. Dia. Med. 30:2300-2301.
24. Perez, M., R. C. Craven, and J. C. de la Torre. 2003. The small RING finger protein Z drives arenavirus budding: implications for antiviral strategies. Proc. Natl. Acad. Sci. U. S. A. 100:12978-12983.
25. Peters, C. J. 2002. Human infection with arenaviruses in the Americas, p. 65-74. In M. B. Oldstone (ed.), Arenaviruses I, vol. 262. Springer-Verlag, Berlin, Germany.
26. Peters, C. J., et al. 1987. Experimental studies of arenaviral hemorrhagic fevers. Curr. Top. Microbiol. Immunol. 134:5-68.
27. Seregin, A. V., et al. 2010. TC83 replicon vectored vaccine provides protection against Junin virus in guinea pigs. Vaccine 28:4713-4718.
28. Strecker, T., et al. 2003. Lassa virus Z protein is a matrix protein and sufficient for the release of virus-like particles. J. Virol. 77:10700-10705. (Pubitemid 37129717)
29. Tortorici, M. A., et al. 2001. Arenavirus nucleocapsid protein displays a transcriptional antitermination activity in vivo. Virus Res. 73:41-55.
30. Urata, S., T. Noda, Y. Kawaoka, H. Yokosawa, and J. Yasuda. 2006. Cellular factors required for Lassa virus budding. J. Virol. 80:4191-4195.
31. Weissenbacher, M. C., R. P. Laguens, and C. E. Coto. 1987. Argentine hemorrhagic fever. Curr. Top. Microbiol. Immunol. 134:79-116.
32. Yun, N. E., et al. 2008. Pathogenesis of XJ and Romero strains of Junin virus in two strains of guinea pigs. Am. J. Trop. Med. Hyg. 79:275-282.